REFERENCES
- Green AR. Protecting the brain: The search for a clinically effective neuroprotective drug for stroke. Crit Rev Neurobiol 2004; 16: 91–97
- Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: Two decades of success and failure. NeuroRx 2004; 1: 36–45
- Schaller B, Graf R. Cerebral ischemia and reperfusion, the pathophysiologic concept as a basis for clinical therapy. Cereb Blood Flow Metab 2004; 24: 351–71
- Warner DS, Sheng H, Batinic-Haberle I. Oxidants, anti-oxidants and the ischemic brain. Exp Biol 2004; 207: 3221–3231
- Leker RR, Shohami E. Cerebral ischemia and trauma-different etiologies yet similar mechanisms: Neuroprotective opportunities. Brain Res Rev 2002; 39: 55–73
- Slevin M, Krupinski J, Kumar P, et al. Gene activation and protein expression following ischaemic stroke: Strategies towards neuro-protection. Cell Mol Med 2005; 9: 85–102
- Sobrado M, Lopez MG, Carceller F, et al. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase BCL-2 expression after focal cerebral ischemia. Neuroscience 2003; 118:107–113
- Rodriguez E, Mendez-Armenta M, Villeda-Hernandez J, et al. Dapsone prevents morphological lesions and lipid peroxidation induced by quinolinic acid in rat corpus striatum. Toxicology 1999; 139:111–118
- Suda T, Suzuki Y, Matsui T, et al. Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner. Br] Dermatol 2005; 152: 887–895
- Rios C, Nader-Kawachi J, Rodriguez-Payan J, et al. Neuroprotective effect of dapsone in an occlusive model of focal ischemia in rats. Brain Res 2004; 999: 212–215
- McIntosh K, Cooper E, Xu J, et al. Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1999; 18: 432–439
- Muir KW, Weir CJ, Murray GD, et al. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke 1996; 27: 1817–1820
- Alonso de Lecifiana A, Perez G, Diez-Tejedor E. Recomenda-ciones para el tratamiento y prevención del ictus. Rev Neurol 2004; 39: 465–486
- Nahata MC, Morosco RS, Trowbridge JM. Stability of dapsone in two oral liquid dosage forms. Ann Pharmacother 2000; 34: 848–850
- Adams HP, Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke 1993; 24: 35–41
- Frankel MR, Morgenstern LB, Kwaitkowski T, et al. Predicting prognosis after stroke: A placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke trial. Neurology 2000; 55: 952–959
- Demchuk AM, Bucham AM. Predictors of stroke outcome. Neurol Clin 2000; 18: 455–473
- Santamaria A, Ordaz-Moreno J, Rubio-Osornio M, et al. Neuroprotective effects of dapsone against quinolinate- and kainate-induced striatal neurotoxicities in rats. Pharmacol Toxicol 1997; 81: 271–275
- Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: Overview and update. J Am Acad Dermatol 2001; 45: 420–434
- Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: Inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997; 62: 827–836
- Garau A, Bertini R, Colotta F, et al. Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine 2005; 30: 125–131